MedTrace Logo

RSPR-007 Mannitol Challenge Trial

NCT02609334 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-11-16

No results posted yet for this study

Summary

This is a double-blind, randomised, placebo-controlled, cross-over, Phase 2 trial evaluating two doses (a low and a high) of CRD007 for the treatment of asthmatic trial subjects with a positive asthma test (mannitol challenge) prior to enrolment.

Conditions

Interventions

DRUG

CRD007

One single dose given 3 hours prior to Mannitol challenge

OTHER

Placebo

One single dose given 3 hours prior to Mannitol challenge

Sponsors & Collaborators

  • RSPR Pharma AB

    lead INDUSTRY

Principal Investigators

  • Vibeke Backer, MD · Bispebjerg Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609334 on ClinicalTrials.gov